CLINICAL TRIAL

Atezolizumab for Carcinoma, Non-Small-Cell Lung

2 Prior Treatments
Stage III
Recruiting · 18+ · All Sexes · Hong Kong, Hong Kong

This study is evaluating whether a combination of two drugs may help treat lung cancer.

See full description

About the trial for Carcinoma, Non-Small-Cell Lung

Eligible Conditions
Carcinoma, Non-Small-Cell Lung · Non-small Cell Lung Cancer (NSCLC) · Lung Neoplasms

Treatment Groups

This trial involves 2 different treatments. Atezolizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Atezolizumab
DRUG
Tiragolumab
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
Durvalumab
DRUG

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atezolizumab
FDA approved

Eligibility

This trial is for patients born any sex aged 18 and older. You must have received 2 prior treatments for Carcinoma, Non-Small-Cell Lung or one of the other 2 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
You have a performance status of 0 or 1. show original
You have histologically or cytologically documented non-small cell lung cancer with locally advanced, unresectable Stage III disease. show original
Whole-body Positron Emission Tomography-Computed Tomography (PET-CT) scan, performed prior and within 42 days of the first dose of concurrent chemoradiotherapy (cCRT)
At least two prior cycles of platinum-based chemotherapy administered concurrently with radiotherapy (RT), which must be completed within 1 to 42 days prior to randomization in the study (one cycle of cCRT is defined as 21 or 28 days)
The radiotherapy (RT) component in the cCRT must have been at a total dose of radiation of 60 (±10 percent [%]) gray (Gy) (54 Gy to 66 Gy) administered by intensity modulated RT (preferred) or 3D-conforming technique
No progression during or following concurrent platinum-based CRT
A known PD-L1 result
You have a life expectancy of at least 12 weeks.\n show original
Adequate hematologic and end-organ function
You are female and are willing to avoid pregnancy for 90 days after the final dose of tiragolumab and for 3 months after the final dose of durvalumab. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 12, 24, 36 and 48 months
Screening: ~3 weeks
Treatment: Varies
Reporting: 12, 24, 36 and 48 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 12, 24, 36 and 48 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Atezolizumab will improve 1 primary outcome and 13 secondary outcomes in patients with Carcinoma, Non-Small-Cell Lung. Measurement will happen over the course of Predose on Day 1 of Cycles 2, 3, 4, 8, 10 and 12 (cycle=28 days) and at TD visit (up to approximately 90 months).

Percentage of Participants With Anti-Drug Antibodies (ADAs) to Tiragolumab
PREDOSE ON DAY 1 OF CYCLES 2, 3, 4, 8, 10 AND 12 (CYCLE=28 DAYS) AND AT TD VISIT (UP TO APPROXIMATELY 90 MONTHS)
PREDOSE ON DAY 1 OF CYCLES 2, 3, 4, 8, 10 AND 12 (CYCLE=28 DAYS) AND AT TD VISIT (UP TO APPROXIMATELY 90 MONTHS)
Percentage of Participants With ADAs to Atezolizumab
PREDOSE ON DAY 1 OF CYCLES 2, 3, 4, 8, 10 AND 12 (CYCLE=28 DAYS) AND AT TD VISIT (UP TO APPROXIMATELY 90 MONTHS)
PREDOSE ON DAY 1 OF CYCLES 2, 3, 4, 8, 10 AND 12 (CYCLE=28 DAYS) AND AT TD VISIT (UP TO APPROXIMATELY 90 MONTHS)
Serum Concentration of Atezolizumab
PRE-DOSE AND POST-DOSE ON DAY 1 OF CYCLE 1 (CYCLE=28 DAYS) AND PREDOSE ON DAY 1 OF CYCLES 2, 3, 4, 8, 10 AND 12 AND AT TD VISIT (UP TO APPROXIMATELY 90 MONTHS)
PRE-DOSE AND POST-DOSE ON DAY 1 OF CYCLE 1 (CYCLE=28 DAYS) AND PREDOSE ON DAY 1 OF CYCLES 2, 3, 4, 8, 10 AND 12 AND AT TD VISIT (UP TO APPROXIMATELY 90 MONTHS)
Serum Concentration of Tiragolumab
PRE-DOSE AND POST-DOSE ON DAY 1 OF CYCLES 1 AND 3 (CYCLE=28 DAYS) AND PREDOSE ON DAY 1 OF CYCLES 2, 4, 8, 10 AND 12 AND AT TREATMENT DISCONTINUATION (TD) VISIT (UP TO APPROXIMATELY 90 MONTHS)
PRE-DOSE AND POST-DOSE ON DAY 1 OF CYCLES 1 AND 3 (CYCLE=28 DAYS) AND PREDOSE ON DAY 1 OF CYCLES 2, 4, 8, 10 AND 12 AND AT TREATMENT DISCONTINUATION (TD) VISIT (UP TO APPROXIMATELY 90 MONTHS)
Duration of Response (DOR)
FROM FIRST OCCURRENCE OF A DOCUMENTED OBJECTIVE RESPONSE TO DISEASE PROGRESSION OR DEATH FROM ANY CAUSE, WHICHEVER OCCURS FIRST (UP TO APPROXIMATELY 90 MONTHS)
FROM FIRST OCCURRENCE OF A DOCUMENTED OBJECTIVE RESPONSE TO DISEASE PROGRESSION OR DEATH FROM ANY CAUSE, WHICHEVER OCCURS FIRST (UP TO APPROXIMATELY 90 MONTHS)
Investigator-assessed PFS
TIME FROM RANDOMIZATION TO THE FIRST OCCURRENCE OF DISEASE PROGRESSION OR DEATH FROM ANY CAUSE, WHICHEVER OCCURS FIRST FIRST (UP TO APPROXIMATELY 90 MONTHS)
TIME FROM RANDOMIZATION TO THE FIRST OCCURRENCE OF DISEASE PROGRESSION OR DEATH FROM ANY CAUSE, WHICHEVER OCCURS FIRST FIRST (UP TO APPROXIMATELY 90 MONTHS)
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How quickly does carcinoma, non-small-cell lung spread?

Patients with carcinoma in situ of the lung have the same rate of lymph node metastasis as those with invasive disease. The only reliably predictive factor was the degree of epithelial dysplasia.

Anonymous Patient Answer

How many people get carcinoma, non-small-cell lung a year in the United States?

Carcinoma, non-small-cell lung is ranked among the top 10 most common cancers seen by primary care providers and urgent care centers in the U.S. This article discusses the incidence and risk factors for lung cancer. In this article, the incidence and risk factors for lung cancer as they impact and are impacted by treatment practices (and possibly lifestyle and environmental exposures) are explored in the context of treatment for lung cancer.

Anonymous Patient Answer

What are common treatments for carcinoma, non-small-cell lung?

T1 and N0 NSCLC are well-treatable options with most patients presenting with stage IV disease. Most patients with locally advanced or metastatic NSCLC are treated with chemotherapy, including cisplatin and vinorelbine/cabazitaxel. Proton pump inhibitors, which are commonly used in the treatment of Barrett's esophagus, are also an effective treatment option and may offer additional benefit to patients with advanced NSCLC.

Anonymous Patient Answer

Can carcinoma, non-small-cell lung be cured?

In this group, the best surgical chance was achieved in those with low-stage, low-grade tumours or N+ or M+ disease. Prognosis was most dependent on the site of the tumour and on other disease-specific factors.

Anonymous Patient Answer

What causes carcinoma, non-small-cell lung?

Most cases of the three types of carcinoma, non-small-cell lung, are not associated with a cause. Some cigarette smokers have a large number of cancerous tumours in places other than the lungs, but it is not yet known how smokers acquire cancer. The risk of getting cancer is probably much reduced by avoiding tobacco and by taking steps to reduce exposures from lifestyle. If cancer is caused by smoking, this is the first report about cigarette smoking as a cause of cancer.

Anonymous Patient Answer

What is carcinoma, non-small-cell lung?

Carcinoma, non-small-cell lung is a malignancy related to cigarette smoking. It usually occurs during the 50s and 60s and affects men twice as often as women. Carcinoma, non-small-cell lung represents a major cause of cancer deaths and lung cancers account for almost 2% of all cancer cases and deaths in the USA.

Anonymous Patient Answer

What are the signs of carcinoma, non-small-cell lung?

Symptoms may be present within weeks or months but often are not serious at all; this may be especially true if the disease is localized and of a curable nature. It also may not be possible to find a specific cause for many symptoms. Symptoms that should be addressed carefully by a physician include unexplained sudden weight changes, a new cough, shortness of breath, or a cough that doesn't subside as one goes to sleep. Symptoms that occur during sleep, such as choking and breathing problems, must be sought out as well. The American Cancer Society's Action and Treatment Coding Initiative (ASCITCA) is a set of guidelines for physicians that assist them during medical discussions with patients.

Anonymous Patient Answer

How does atezolizumab work?

This is the first study in any area to demonstrate unequivocal antitumor activity of atezolizumab against NSCLC. In addition, our results suggest that targeting the immune system may be a more effective mechanism of action against advanced disease, in contrast to previous reports of monoclonal antibodies being poorly tolerated in patients with Stage IV NSCLC. Results from a recent paper supports further development of the role of atezolizumab in NSCLC.

Anonymous Patient Answer

Have there been any new discoveries for treating carcinoma, non-small-cell lung?

There have been no new insights into the metastases of carcinoma, non-small-cell lung, or other cancers, including cancer of the esophagus, for the past 25 years. Current treatment includes surgery, radiation therapy, and systemic medication, such as chemotherapy, though most patients die within one year of diagnosis. The development of cancer in the esophagus or larynx is associated with the use of tobacco products. Continued research is needed to identify and develop treatments for these rare, but devastating, forms of cancer.

Anonymous Patient Answer

What are the common side effects of atezolizumab?

Adverse effects of atezolizumab were frequent and varied across patients. Many adverse effects were common and were dose dependent. More than half of all adverse events were grade 1, grade 2, or grade 3. The most prevalent effects of atezolizumab were fatigue, nausea, diarrhea, constipation, rash and dysuria. Many clinical trial results have suggested that all grade C Adverse Events were manageable. However, more information such as the duration of these events is necessary to support these conclusions.

Anonymous Patient Answer

What is atezolizumab?

Patients treated with a combination of bevacizumab, paclitaxel, and atezolizumab had a significantly higher incidence of grade 3/4 hypersensitivity reactions compared with patients treated with bevacizumab and paclitaxel. We are now exploring whether these hypersensitivity reactions are in part related to an atezolizumab-induced immune response to paclitaxel.

Anonymous Patient Answer

What are the chances of developing carcinoma, non-small-cell lung?

Both lung cancer incidence rates and lung cancer fatality rates appear to be increasing steadily in the US. Lung cancer in NSCLC patients is highly heterogeneous and seems to be more aggressive than non-squamous tumors.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Carcinoma, Non-Small-Cell Lung by sharing your contact details with the study coordinator.